# Tirzepatide vs Eloralintide: How They Differ | PepVault

Source: https://pepvault.app/peptides/compare/tirzepatide-vs-eloralintide

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Comparisons](https://pepvault.app/peptides/compare) Tirzepatide vs Eloralintide

Compared side by side

# Tirzepatide vs eloralintide: how they differ

Reviewed November 2026 [How we check the library](https://pepvault.app/about#library) [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The short answer

They act on different hormones: tirzepatide activates the GLP-1 and GIP receptors, and eloralintide is a selective agonist of the amylin receptor, the receptor for the fullness hormone the pancreas releases with insulin. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; eloralintide, from Eli Lilly, has been in phase 3 since late 2025 and isn’t approved anywhere. Both are weekly shots, and in their own trials tirzepatide’s 15 mg produced up to 22.5% weight loss at 72 weeks (SURMOUNT-1), and eloralintide’s 9 mg about 20% at 48 weeks in phase 2.

## Side by side

| Compared | [Tirzepatide](https://pepvault.app/peptides/tirzepatide) | [Eloralintide](https://pepvault.app/peptides/eloralintide) |
| --- | --- | --- |
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Mounjaro, Zepbound, LY3298176 | LY3841136, Elora |
| What it is | The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). | A once-weekly amylin drug from Eli Lilly, built to copy the fullness hormone the pancreas releases with insulin, and to act on its receptor more selectively than cagrilintide does. |
| How it works | Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management. | Once-weekly, long-acting agonist of the amylin receptor, the receptor for amylin, the fullness hormone the pancreas releases with insulin. Unlike cagrilintide, it is selective: it acts far more on amylin receptors than on the calcitonin receptor, a difference Lilly thinks may make it easier on the stomach. The idea is fewer calories through earlier fullness after meals rather than through the GLP-1 pathway. Its half-life of about 14 days keeps blood levels nearly flat across the week. Investigational, from Eli Lilly, in phase 3 since late 2025. |
| Commonly reported | Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound). | In trials, fewer cravings, especially for sugar, and less food noise, with nausea and tiredness more likely on the higher doses. It is in phase 3 and not approved anywhere. |
| Studied range | FDA label: 2.5–15 mg, starting dose 2.5 mg. | Research range: 1–9 mg, starting dose 3 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~5 days (FDA label) | ~14 days (measured in people: phase 1 trials, Bhattachar 2026) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose. | Used continuously, once weekly, in its trials: 12 weeks in phase 1 and 48 weeks in phase 2; phase 3 runs about 75 weeks. No trial has tested stopping it. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue | Nausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction |

Typical run: Community practice — opinions vary. Not a clinical recommendation.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking tirzepatide or eloralintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

### Tirzepatide

- Day 1–28 · 2.5 mg Getting your gut acclimated
- Day 29–56 · 5 mg First therapeutic dose — weight drops
- Day 57–112 · 7.5 mg Dual agonism in full effect
- Day 113–168 · 12.5 mg Max titration reached
- Day 169–504 Weeks 24 to 72: where most people plateau
- Day 365+ A maintenance medication, not a course

[Every card for tirzepatide, with its sources](https://pepvault.app/peptides/tirzepatide#weeks)

### Eloralintide

- Day 1–28 · 3 mg Fullness first, gently
- Day 29–56 · 6 mg The step where nausea shows up
- Day 57–336 · 6 mg Holding at 6 mg
- Day 57–336 · 9 mg The top dose tested
- Day 85–336 Fewer cravings, quieter food noise
- Day 337+ A long-term medicine, not a course

[Every card for eloralintide, with its sources](https://pepvault.app/peptides/eloralintide#weeks)

## Together or one or the other

Tirzepatide and eloralintide are a common stack: eloralintide lists tirzepatide among its common stacks.

RCT · Eloralintide

### Eloralintide with tirzepatide

Lilly is testing the two together as EloraTZP, amylin plus GIP and GLP-1. In a 48-week trial in type 2 diabetes, the top pair averaged about 23% weight loss vs about 15% on tirzepatide alone. Side effects were more common in the pairs, mostly while doses were stepping up.

## With this comparison

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Eloralintide

- [Eloralintide: the full reference](https://pepvault.app/peptides/eloralintide)
- [Eloralintide dose guide](https://pepvault.app/lab/dosage/eloralintide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Eloralintide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/eloralintide-10mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)
- [Eloralintide: 2.6% to 11.3% weight loss at 12 weeks in phase 1](https://pepvault.app/research/eloralintide-bhattachar-2026)
- [Eloralintide: -4.4% body weight at week 4 in a single-dose trial](https://pepvault.app/research/eloralintide-briere-2025)
- [All 2 studies](https://pepvault.app/research#eloralintide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Stack](https://pepvault.app/glossary/stack)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)

## Questions people ask

### How long do tirzepatide and eloralintide last?

The half-life of tirzepatide is ~5 days (FDA label). The half-life of eloralintide is ~14 days (measured in people: phase 1 trials, Bhattachar 2026).

### How often are tirzepatide and eloralintide taken?

Tirzepatide: weekly. Route: SubQ injection. Eloralintide: weekly. Route: SubQ injection.

### How are tirzepatide and eloralintide dosed in research?

The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The research range for eloralintide is 1–9 mg, with a 3 mg starting dose. Studied in research — not a recommendation.

### What are the common side effects of tirzepatide and eloralintide?

For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For eloralintide: nausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction.

### Are tirzepatide and eloralintide taken together?

Tirzepatide and eloralintide are a common stack: eloralintide lists tirzepatide among its common stacks. Lilly is testing the two together as EloraTZP, amylin plus GIP and GLP-1. In a 48-week trial in type 2 diabetes, the top pair averaged about 23% weight loss vs about 15% on tirzepatide alone. Side effects were more common in the pairs, mostly while doses were stepping up.

## Each one in full

- [Tirzepatide: dosage, half-life & reference guide](https://pepvault.app/peptides/tirzepatide)
- [Eloralintide: dosage, half-life & reference guide](https://pepvault.app/peptides/eloralintide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)
- [Eloralintide dose guide](https://pepvault.app/lab/dosage/eloralintide)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking tirzepatide or eloralintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking tirzepatide or eloralintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this comparison

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Eloralintide

- [Eloralintide: the full reference](https://pepvault.app/peptides/eloralintide)
- [Eloralintide dose guide](https://pepvault.app/lab/dosage/eloralintide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Eloralintide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/eloralintide-10mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)
- [Eloralintide: 2.6% to 11.3% weight loss at 12 weeks in phase 1](https://pepvault.app/research/eloralintide-bhattachar-2026)
- [Eloralintide: -4.4% body weight at week 4 in a single-dose trial](https://pepvault.app/research/eloralintide-briere-2025)
- [All 2 studies](https://pepvault.app/research#eloralintide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Stack](https://pepvault.app/glossary/stack)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)

<!--promo-->

PepVault for iPhone

## Taking tirzepatide or eloralintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## More comparisons

- [All peptide comparisons](https://pepvault.app/peptides/compare)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

## The library

- [The peptide reference library](https://pepvault.app/peptides)
- [Metabolic & GLP-1 peptides](https://pepvault.app/peptides#metabolic)

## Free tools

- [The Dose Guide](https://pepvault.app/lab/dosage)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity are trademarks of their respective owners; PepVault is independent and not affiliated with or endorsed by any manufacturer.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
